INCY
$90.78-2.17 (-2.33%)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
Recent News
Is Incyte Stock Outperforming the Dow?
Incyte has outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.
Incyte at Barclays: Maps Post-Jakafi Growth With New Launches and Phase III Pipeline Push
Incyte (NASDAQ:INCY) executives outlined the company’s near-term launch priorities and mid-stage pipeline plans during a presentation at the Barclays conference, emphasizing a strategy to sustain growth ahead of the loss of exclusivity for Jakafi in 2029. Chief Executive Officer Bill Meury said the
Incyte’s Latin American MINJUVI Steps Expand Oncology Story Beyond Jakafi
Knight Therapeutics secured Brazilian approval for an expanded indication of MINJUVI (tafasitamab), a lymphoma therapy partnered with Incyte. The company also filed for the same new indication in Argentina and Mexico, beginning broader Latin American regulatory outreach. These steps represent the first approvals and filings for MINJUVI's new use in the region and add treatment options for lymphoma patients. The development highlights progress in Incyte's international oncology pipeline...
1 Cash-Heavy Stock to Target This Week and 2 Facing Headwinds
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
Qualcomm, Adobe downgraded: Wall Street's top analyst calls
Qualcomm, Adobe downgraded: Wall Street's top analyst calls